CTMX
Price
$2.06
Change
-$0.12 (-5.50%)
Updated
Sep 9, 12:41 PM (EDT)
Capitalization
359.51M
58 days until earnings call
FATE
Price
$0.94
Change
-$0.03 (-3.09%)
Updated
Sep 9, 12:45 PM (EDT)
Capitalization
111.41M
51 days until earnings call
Interact to see
Advertisement

CTMX vs FATE

Header iconCTMX vs FATE Comparison
Open Charts CTMX vs FATEBanner chart's image
CytomX Therapeutics
Price$2.06
Change-$0.12 (-5.50%)
Volume$12.58K
Capitalization359.51M
Fate Therapeutics
Price$0.94
Change-$0.03 (-3.09%)
Volume$6.18K
Capitalization111.41M
CTMX vs FATE Comparison Chart in %
Loading...
CTMX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CTMX vs. FATE commentary
Sep 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CTMX is a Hold and FATE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 09, 2025
Stock price -- (CTMX: $2.18 vs. FATE: $0.97)
Brand notoriety: CTMX and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CTMX: 127% vs. FATE: 84%
Market capitalization -- CTMX: $359.51M vs. FATE: $111.41M
CTMX [@Biotechnology] is valued at $359.51M. FATE’s [@Biotechnology] market capitalization is $111.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CTMX’s FA Score shows that 1 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • CTMX’s FA Score: 1 green, 4 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, CTMX is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CTMX’s TA Score shows that 4 TA indicator(s) are bullish while FATE’s TA Score has 4 bullish TA indicator(s).

  • CTMX’s TA Score: 4 bullish, 5 bearish.
  • FATE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, FATE is a better buy in the short-term than CTMX.

Price Growth

CTMX (@Biotechnology) experienced а +6.86% price change this week, while FATE (@Biotechnology) price change was -7.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was +10.49%, and the average quarterly price growth was +34.78%.

Reported Earning Dates

CTMX is expected to report earnings on Nov 06, 2025.

FATE is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+1.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CTMX($360M) has a higher market cap than FATE($111M). CTMX YTD gains are higher at: 111.651 vs. FATE (-41.455). CTMX has higher annual earnings (EBITDA): 44.7M vs. FATE (-161.6M). FATE has more cash in the bank: 223M vs. CTMX (158M). CTMX has less debt than FATE: CTMX (6.89M) vs FATE (81.3M). CTMX has higher revenues than FATE: CTMX (141M) vs FATE (8.47M).
CTMXFATECTMX / FATE
Capitalization360M111M324%
EBITDA44.7M-161.6M-28%
Gain YTD111.651-41.455-269%
P/E Ratio4.36N/A-
Revenue141M8.47M1,665%
Total Cash158M223M71%
Total Debt6.89M81.3M8%
FUNDAMENTALS RATINGS
CTMX vs FATE: Fundamental Ratings
CTMX
FATE
OUTLOOK RATING
1..100
260
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1398
PRICE GROWTH RATING
1..100
3687
P/E GROWTH RATING
1..100
94100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (13) in the Biotechnology industry is in the same range as CTMX (39). This means that FATE’s stock grew similarly to CTMX’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CTMX (100). This means that FATE’s stock grew similarly to CTMX’s over the last 12 months.

CTMX's SMR Rating (13) in the Biotechnology industry is significantly better than the same rating for FATE (98). This means that CTMX’s stock grew significantly faster than FATE’s over the last 12 months.

CTMX's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for FATE (87). This means that CTMX’s stock grew somewhat faster than FATE’s over the last 12 months.

CTMX's P/E Growth Rating (94) in the Biotechnology industry is in the same range as FATE (100). This means that CTMX’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CTMXFATE
RSI
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 14 days ago
86%
Declines
ODDS (%)
Bearish Trend 12 days ago
87%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 6 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
CTMX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BOIVF5.690.08
+1.43%
Bollore Investissement
BLMWF1.000.01
+1.01%
BluMetric Environmental, Inc.
KSIOF3.990.02
+0.43%
kneat.com, Inc.
MRIRF0.11N/A
N/A
Route 109 Resources Inc.
VRBCF346.00N/A
N/A
Virbac SA

CTMX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CTMX has been loosely correlated with BCAB. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CTMX jumps, then BCAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CTMX
1D Price
Change %
CTMX100%
-4.39%
BCAB - CTMX
37%
Loosely correlated
+13.92%
THRD - CTMX
37%
Loosely correlated
N/A
RAPT - CTMX
34%
Loosely correlated
+2.71%
KZR - CTMX
34%
Loosely correlated
-1.47%
FATE - CTMX
33%
Loosely correlated
-4.36%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with RXRX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-4.36%
RXRX - FATE
53%
Loosely correlated
+0.22%
CRBU - FATE
52%
Loosely correlated
-3.21%
MGNX - FATE
52%
Loosely correlated
-12.00%
ALLO - FATE
51%
Loosely correlated
-0.87%
NTLA - FATE
50%
Loosely correlated
-1.82%
More